PCD Connectathon&Showcase 2010-09-21 Webex: Difference between revisions

From IHE Wiki
Jump to navigation Jump to search
Efurst (talk | contribs)
m Participants: begin entering summary
Efurst (talk | contribs)
m partial entry
Line 28: Line 28:
| '''Introductions & Agenda Review''' <br>- Manny
| '''Introductions & Agenda Review''' <br>- Manny
| '''Status/Discussion:'''
| '''Status/Discussion:'''
: '''placeholder'''  No changes were made to the agenda  
: Newcomers were introduced. No changes were made to the agenda.
:  
:  
'''Decisions/Issues:'''
'''Decisions/Issues:'''
Line 36: Line 36:
|-
|-
| align="center" | 2
| align="center" | 2
| '''Introductions, Orientation ''' <br>-  
| '''Action Items From Last Week ''' <br>- All
| '''Status/Discussion:'''  '''to be discussed:'''
| '''Status/Discussion:'''   
 


'''Decisions/Issues:'''
'''Decisions/Issues:'''
Line 46: Line 45:
|-
|-
| align="center" | 3
| align="center" | 3
| '''Brief Overview ''' <br>- Manny
| ''' ''' <br>- Manny
| '''Status/Discussion:'''   
| '''Status/Discussion:'''   
*  
* The Four Scenarios Plus One or Two
 
:Manny will update the Scenarios with the changes developed during the meeting. Each wall will emphasize one PCD profile as Anupriyo suggested last week.
 
* Scenario 1: Emphasis on PIV: Continua is to be removed. Pfizer is interested in demonstrating Adverse Event Reporting to the FDA. If space and time permits this will be part of Scenario 1 on the wall or elsewhere (cross setting). It would address an adverse event caused by a device, and make use of the medical record for patient data and device identification.
 
* Scenario 2: Emphasis on ACM: Add PCD-06, PCD-07 to all steps.
 
* Scenario 3: Emphasis on DEC with many different types of systems: Oz System provides a hearing screening report to public health agencies. Their system takes data from hearing test devices and they want to send it as PCD-01 to other devices systems, e.g., a medical record system. They also want to consume PCD-01 from hearing devices. This would supplement fetal monitoring and other infant data.
 
* Scenario 4: Emphasis on IDCO: No changes.
 
* Scenario 5: Meaningful Use: TBD.
 
* Scenario 6: Placeholder for the FDA Adverse Event Reporting story which may not be physically located at PCD.
 





Revision as of 20:02, 23 September 2010

PCD Connectathon & Showcase Tenth Meeting, September 21, 2010

Action Items

You can find the Action Items at http:___

Agenda

You can find the agenda at http://wiki.ihe.net/index.php?title=PCD_Connectathon%26Showcase_WG_2010-11

Participants

Bob Britton, Michael Celeste (Pfizer), Bikram Day, John Donnelly, Al Engelbert, Robert Flanders, Ken Fuchs, John Garguilo, Dina Lappe (Philips), Brad Lunde, Geri Mitchell-Brown, Monroe Pattillo, Ken Pool (Oz Systems), Sandy Vance (HIMSS), Manny Furst

Newcomers were welcomed (see affiliations in parentheses).

Discussion

Item Topic Discussion
1 Introductions & Agenda Review
- Manny
Status/Discussion:
Newcomers were introduced. No changes were made to the agenda.

Decisions/Issues:

Action(s):

2 Action Items From Last Week
- All
Status/Discussion:

Decisions/Issues:

Action(s):

3
- Manny
Status/Discussion:
  • The Four Scenarios Plus One or Two
Manny will update the Scenarios with the changes developed during the meeting. Each wall will emphasize one PCD profile as Anupriyo suggested last week.
  • Scenario 1: Emphasis on PIV: Continua is to be removed. Pfizer is interested in demonstrating Adverse Event Reporting to the FDA. If space and time permits this will be part of Scenario 1 on the wall or elsewhere (cross setting). It would address an adverse event caused by a device, and make use of the medical record for patient data and device identification.
  • Scenario 2: Emphasis on ACM: Add PCD-06, PCD-07 to all steps.
  • Scenario 3: Emphasis on DEC with many different types of systems: Oz System provides a hearing screening report to public health agencies. Their system takes data from hearing test devices and they want to send it as PCD-01 to other devices systems, e.g., a medical record system. They also want to consume PCD-01 from hearing devices. This would supplement fetal monitoring and other infant data.
  • Scenario 4: Emphasis on IDCO: No changes.
  • Scenario 5: Meaningful Use: TBD.
  • Scenario 6: Placeholder for the FDA Adverse Event Reporting story which may not be physically located at PCD.


Decisions/Issues:

Action(s):

4 Webinars
- Manny
Status/Discussion:

Decisions/Issues:

Action(s):

5 Registration
- Manny
Status/Discussion:


Decisions/Issues:

Action(s):


6 Lessons Learned
- ___
Status/Discussion:


Decisions/Issues:

Action(s):


7 Issues and Questions
- ___
Status/Discussion:

Decisions/Issues:

Action(s):


8 New Business
- All
Status/Discussion:

Decisions/Issues:

Action(s):


9 Next Meeting
- All
Status/Discussion:


Decisions/Issues:

Action(s):


Return to main WG page which has links to individual meeting pages

Return to main PCD Connectathon/Showcase WG page: PCD_Connectathon&Showcase_WG_2010-11